New MenaQ7 patents granted to NattoPharma in US, Israel and Australia

6b8015c8-ad96-4c8c-a133-ab76615dc355articleimage.jpg

08 Nov 2017 --- NattoPharma ASA has successfully secured patents in Israel, the US and Australia for its “nature-identical synthesis” creating MenaQ7 PharmaPure Vitamin K2 as MK-7, adding further to the company’s patent portfolio.

“These patents underline our position as the leader in the vitamin K2 market,” Kjetil Ramsøy, NattoPharma Chief Financial Officer, tells NutritionInsight. “Having the most clinically validated vitamin K2 as MK-7 available today, and the only all-trans nature-identical synthetic available that is free of cis-isomers, this will give our partners the validation they need to ensure they are serving their customers the best possible product.”

Global success with patents
NattoPharma details the company’s progress with patents:

  • Israel: On July 31, 2017, patent #238199 “Process for preparation of MK-7 type of Vitamin K2” was granted.
  • US: On August 28, 2017, Notice of Allowance for patent #14/435,260 “Process for preparation of MK-7 type vitamin K2” was issued.
  • Australia: On July 5, 2017, Notice of Acceptance (NoA) was issued for patent #2013330517 “process for preparation of MK-7 type of vitamin K2.” This NoA was published on July 20.

“This unique patented process results in the world’s only truly all-trans synthetic vitamin K2 as MK-7,” says William Sommer, NattoPharma’s Vice President of Global Development & Regulatory. “Our material is of the highest quality and superior to anything else on the market, so much so that it is currently being utilized in two studies sponsored by the traditional medical community.”

“These studies are evidence that the medical community recognizes the difference a vitamin can make for human health, and in selecting MenaQ7 PharmaPure, they want to use the purest, all-trans material for future further confirmation and discovery of health benefits,” he continues. “This technology also ensures supplement providers deliver the MK-7 with the health benefits consumers desire.”

Sommer adds that NattoPharma has made significant intellectual and monetary investments technologies in, and that the company is committed to actively monitor market developments to protect the company’s intellectual property rights throughout their lifespan.

“The approval of these patents represents another milestone for NattoPharma and our partners,” concludes Sommer. “This further strengthens NattoPharma’s global intellectual property rights platform and improves our competitive position within the food supplement market.”

“We see a very positive development in the interest in vitamin K2, which is also supported by our global growth over the last couple of years,” Ramsøy notes to NutritionInsight. “We expect this to continue in the coming years as the knowledge about the benefits of Vitamin K2 grows even more in the consumer market.”

There are also plans to obtain patents for MenaQ7 in further countries. “Patents are currently pending in a number of different jurisdictions, both for the synthetic production patent for PharmaPure, as well as for different health claims related to the use of vitamin K2 as a dietary supplement,” Ramsøy explains.

By Paul Creasy

To contact our editorial team please email us at editorial@cnsmedia.com

NattoPharma ASA

Collapse

As the leader in Vitamin K2 research & development, NattoPharma has not only created the Vitamin K2 category, but continues to drive it forward. Offering the best and first clinically validated and patented Vitamin K2 as MK-7 on the market, MenaQ7®, NattoPharma has sponsored the groundbreaking research that has confirmed K2’s essential role in bone and cardiovascular health, for old and young alike.

NattoPharma’s mission is to advance global health by creating and introducing to the market scientifically validated products and technologies that will deliver measurable health benefits and optimal health outcomes.

This mission is accomplished by:

• Addressing significant health concerns with branded, scientifically validated, proprietary products and technologies, leading with our flagship brand MenaQ7®;

• Leveraging all manner of technology to more effectively and efficiently deliver these products to our target markets;

• Solidifying ourselves as the experts in the science underlying our products and associated enabling technologies that allow us to effectively deliver them to the marketplace; and

• Developing and maintaining a deep customer and segment understanding of the benefits we deliver.

With 19+ published studies and even more underway, NattoPharma has an unparalleled patent portfolio related to relevant health benefits and market segments, creating extra values for its customers.  

MenaQ7® meets the growing demand for highly pure, stable K2 for supplemental and food use in any different format.

The most comprehensive Vitamin K2 ingredient portfolio meeting market needs:

MenaQ7® Natural MK-7: 96% pure all-trans MK-7 free of soy and other allergens.

MenaQ7® PharmaPure MK-7: The only all-trans nature-identical synthetic, winner of 2015   NutrAward for Best Functional Ingredient

MenaQ7® Natto MK-7: 96% active all-trans soy fermented MK-7

MenaQ7® Full Spectrum K2: The first and only K2 to deliver menaquinone isomers MK-6, 7, 8, and 9, free from soy and other allergens.

All material is available with CryoCap microencapsulation, ensuring stable menaquinone protection in any formulation.

The MenaQ7® brand is built upon 6 Pillars of Excellence, a platform delivering the most safe and efficacious Vitamin K2 on the market, creating opportunities for manufacturers and value for end users:

• Trusted Expertise

• Science Leader

• Superior Products

• Continuous Innovation

• Educational Marketing

• Cooperative Support

Visit website for more information: www.menaq7.com 

Related Articles

Health & Nutrition News

Symprove multi-strain supplement linked to re-balancing of gut microbiome

20 Nov 2018 --- “Good” bacteria in the live probiotic Symprove can successfully reach and colonize the gut, where they can modify existing gut flora, according to new research published in the International Journal of Pharmaceutics. Researchers also noted that these bacteria are capable of modifying the immune response in the human body.

Health & Nutrition News

Metabolic surgery: Transformational or quick-fix?

19 Nov 2018 --- More than one-third of US adults are obese and some of the lead causes of non-communicable disease’ deaths – such as stroke, diabetes and cancers – are obesity-related. Although a healthy diet and lifestyle are key to healthy weight management, more drastic measures, such as bariatric surgery, are becoming more commonplace as obesity levels rise. NutritionInsight takes a look into the discussion around bariatric surgery, following research presented during last week’s Obesity Week event based in Tennessee, US.

Health & Nutrition News

Health Logics launches mood and cognition-enhancing supplement

16 Nov 2018 --- Health Logics is launching a dietary supplement containing S-adenosylmethionine. Also known as SAM-e, produced by advanced biotech company Gnosis, the ingredient is touted as improving joint, brain and liver function, and enhances mood and cognition.

Health & Nutrition News

Student lunch picks: Milk and fruit losing out to fruit juice, study finds

16 Nov 2018 --- High school students participating in school meal programs are less likely to select milk, whole fruit and water when fruit juice is available, which on balance may decrease the nutritional quality of their lunches, according to a new study by the Rudd Center for Food Policy and Obesity at the University of Connecticut.

Health & Nutrition News

Deep sea dinners? Future global food source may lie in cephalopods, study says

15 Nov 2018 --- As the world’s population continues to expand and worries over strained global food resources grow, a recent article published in Frontiers is highlighting how cephalopods – squid, octopus and cuttlefish – could hold promise for our nutritional future. Under the initiative CephsInAction, the article calls for the use of the cephalopod population as a growing source of protein and a counterweight to the pressures facing global fisheries.

More Articles
URL : http://www.nutritioninsight.com:80/news/new-menaq7-patents-granted-to-nattopharma-in-us-israel-and-australia.html